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Summary 
Introduction 
The standard recommended treatment for neurogenic detrusor overactivity 
(NDO) is clean intermittent catheterization combined with an antimuscarinic 
agent. However, the adverse systemic side effects of oxybutynin, the most 
widely used agent, are of concern. 
Objective 
To evaluate the efficacy and safety of solifenacin in pediatric patients with NDO, 
aged 6 months–<5 years and 5–<18 years. 
Study design 
Two open-label, baseline-controlled, phase 3 studies were conducted in 
pediatric patients with NDO. Patients were treated with sequential doses of 
solifenacin oral suspension (pediatric equivalent doses 2.5–10 mg) for 
12 weeks to determine each patient’s optimal dose, followed by a fixed dose 
≥40-week treatment period. Primary efficacy endpoint was change from 
baseline in maximum cystometric capacity (MCC) after 24 weeks. Secondary 
endpoints included bladder compliance, bladder volume until first detrusor 
contraction (>15 cmH2O), number of overactive detrusor contractions 
(>15 cmH2O), maximum catheterized volume (MCV)/24 h and incontinence 
episodes/24 h. Safety parameters were treatment-emergent adverse events 
(TEAEs), serious adverse events, laboratory variables, vital signs, 
electrocardiograms, and ocular accommodation and cognitive function 
assessments. 
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Results 
After 24 weeks, MCC had significantly increased compared with baseline in 
patients aged 6 months–<5 years and 5–<18 years (37.0 ml and 57.2 ml, 
respectively; P < 0.001; Fig.). Improvement was also observed after 52 weeks’ 
treatment. Significant changes were observed from baseline to week 24 in all 
secondary endpoints in both age groups: increase in bladder compliance, 
increase in bladder volume to first detrusor contraction as a percentage of 
expected bladder capacity, reduction in the number of overactive detrusor 
contractions, increase in MCV, and decreased incontinence episodes. TEAEs 
were mostly mild or moderate and there were no new drug-related TEAEs 
compared with adult studies. Age-related improvements were noted in ocular 
accommodation and cognitive function. 
Discussion 
These long-term multicenter investigations demonstrated the efficacy and safety 
of solifenacin in pediatric patients with NDO. The observed increases in MCC 
were clinically relevant and demonstrated that an increase in fluid volume can 
be accommodated in the bladder prior to reaching intravesical pressures that 
endanger kidney function and/or are associated with leakage or discomfort. 
Solifenacin was well tolerated with low incidences of constipation and dry mouth 
(typically associated with antimuscarinics), central nervous system-related side 
effects and facial flushing. 
Conclusion 
Solifenacin was effective and well tolerated in pediatric patients with NDO, aged 
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6 months–<18 years, suggesting that it is a viable alternative to oxybutynin, the 
current standard of care. 
Studies are registered at ClinicalTrials.gov: NCT01981954 and NCT01565694 
 
Summary Fig. MCC of patients aged 6 months–<5 years and 5–<18 years at 
baseline and week 24 (primary endpoint) and week 52 (secondary endpoint; full 
analysis set). 
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Introduction 
Neurogenic detrusor overactivity (NDO) is defined as the occurrence of 
involuntary detrusor contractions during filling cystometry that have a relevant 
neurological cause [1]. Epidemiology data in the pediatric population are limited; 
in 2009, an estimated 17 170 pediatric patients in the EU were diagnosed with 
NDO (prevalence: 1.8/10 000 children) [2]. NDO is predominantly caused by a 
congenital neural tube defect in children [3]. The detrusor of patients with NDO 
contracts involuntarily during bladder filling, which simultaneously coincides with 
sphincter dyssynergia, and results in high bladder pressure and eventual renal 
damage [4]. Clinically, we typically find the majority of children with congenital 
neural tube defects present with both detrusor instability and sphincter 
dyssynergia. 
Goals for NDO management are to prevent or minimize upper urinary tract 
damage and achieve social continence [5]. Clean intermittent catheterization 
(CIC) combined with antimuscarinic agents is the standard recommended 
treatment [6]. The antimuscarinic oxybutynin is approved in patients aged ≥5 
years and trospium is approved for older children (≥12 years) in some countries 
[7]. Although widely used, oxybutynin has been associated with adverse 
systemic effects including cognitive impairment in children [8,9], a well-known 
undesirable effect in adults. Concerns about adverse central nervous system 
(CNS) effects in pediatric patients with NDO have resulted in a need for a drug 
with a lower potential for such effects. 
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The antimuscarinic solifenacin succinate (VESIcare®, Astellas Pharma Europe, 
B.V., The Netherlands) is approved worldwide for the treatment of adult 
overactive bladder (OAB) symptoms [10], and is effective and well tolerated in 
adults with either OAB [11-13] or NDO [14]. 
An oral suspension of solifenacin, developed to enable comfortable 
administration and flexible dosing in the pediatric population, has proven to be 
efficacious and well tolerated in pediatric patients with OAB [15,16]. In a 
prospective open-label study, an adjusted-dose solifenacin regimen had high 
subjective and objective success rates for the treatment of NDO in pediatric 
patients refractory to oxybutynin or tolterodine [17]. Following this previous 
investigation, the current studies were conducted to assess whether the efficacy 
and safety of solifenacin oral suspension could be maintained long term in 
pediatric patients with NDO. Results from these studies contributed to European 
approval of solifenacin treatment for NDO in patients aged 2–18 years. 
 
Materials and methods 
Study design 
Two open-label, baseline-controlled, multicenter, sequential-dose titration, 
phase 3 studies were conducted in pediatric patients, aged 6 months–<5 years 
(MARMOSET; NCT01981954; September 2013–December 2015) and 5–<18 
years (MONKEY; NCT01565694; August 2012–April 2016), diagnosed with 
NDO according to International Children’s Continence Society (ICCS) criteria 
and using CIC [18]. A staggered approach was followed during enrollment, 
starting with the adolescents and conducting a safety assessment before 
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enrolling children aged 5–<12 years, 2–<5 years, and 6 months–<2 years. 
Enrolled patients who satisfied the inclusion criteria during screening (Appendix 
Table A) were administered solifenacin oral suspension. The starting dose in 
children aged ≥2 years was initially an allometrically scaled pediatric equivalent 
of the adult 5 mg dose (PED5), revised to a physiologically based 
pharmacokinetic-determined dose of PED2.5 for children aged 6 months–<5 
years following a protocol amendment to include patients who were 6 months–
<2 years. Solifenacin was titrated up or down every 3 weeks over a 12-week 
period to an optimal once-daily final dose of PED2.5, PED5, PED7.5, or PED10 
(Fig. 1). The decision to titrate was according to investigator discretion based on 
diary and safety parameters: (i) if the patient was incontinent but did not 
experience intolerable adverse events (AEs), or if there were high pressure 
contractions (>40 cmH2O) and/or a bladder compliance of <10 mL/cmH2O, the 
dose was titrated up to next highest dose; (ii) if the patient experienced 
intolerable AEs, the dose was titrated down to next lowest dose (iii) if the patient 
was incontinence-free and did not experience intolerable AEs, the dose 
remained the same. A minimum 40-week fixed dose assessment period started 
when the optimal dose for each patient was reached (i.e., a maximum 52 
weeks’ treatment). 
Recruitment of patients was dependent on satisfactory review of data and 
recommendations made by an independent Data and Safety Monitoring Board 
who met at regular intervals. No concerns were raised at any of the meetings. 
Both studies were approved by the Independent Ethics Committee/Institutional 
Review Board for each site. The patient’s parent(s)/legal guardian(s) provided 
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informed consent, and where appropriate, the patient provided written assent. 
The studies were conducted in accordance with Good Clinical Practice, 
International Council for Harmonisation guidelines and the ethical principles of 
the Declaration of Helsinki. 
 
Efficacy assessments 
Urodynamic assessments were performed in unsedated patients at baseline, 
during the titration period and at week 24; an optional assessment was 
performed at week 52. Patients and/or parent(s)/legal representative(s) 
completed a 3-day diary for patients aged 6 months–<5 years or a 7-day diary 
for patients aged 5–<18 years, on the number of catheterizations, catheterized 
volumes, and incontinence episodes (leakage) before visit 2 and all subsequent 
visits. 
The primary efficacy endpoint was change from baseline to week 24 in 
maximum cystometric capacity (MCC), defined as maximum bladder capacity 
reached during filling cystometry before either leakage or pain/discomfort was 
observed or 135% of expected bladder capacity (EBC) was reached [19]. The 
secondary efficacy variables based on urodynamic assessments were change 
from baseline to week 52 in MCC and change from baseline to week 24 and 
week 52 in bladder compliance (measured at a point agreed by two 
investigators prior to a detrusor contraction or sudden spike in pressure), 
bladder volume until first detrusor contraction (>15 cmH2O) expressed as a 
percentage of EBC, bladder volume at 10, 20 and 30 cmH2O (individuals aged 
6 months–<5 years) or 20, 30 and 40 cmH2O (individuals aged 5–<18 years), 
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and number of overactive detrusor contractions (>15 cmH2O) until leakage or 
end of bladder filling. Secondary efficacy variables based on patient diaries 
were changes from baseline to each post-baseline visit (up to week 52) in 
maximum catheterized volume (MCV)/24 h and incontinence episodes/24 h. 
Exploratory analyses were performed to express MCC as a percentage of EBC 
or MCV. 
 
Safety assessments 
Safety assessments performed at each study visit included incidences of 
treatment-emergent adverse events (TEAEs), vital signs (systolic blood 
pressure, diastolic blood pressure, pulse rate, and body temperature versus 
standard norms) [20], laboratory variables (hematology, biochemistry, and 
urinalysis), 12-lead electrocardiograms (ECGs), height and weight versus 
growth charts [21], and ultrasound assessments of the upper urinary tract. 
Patients aged 5–<18 years underwent tests for ocular accommodation 
(accommodative response profile over 0 to 4.5 diopters and the accommodative 
error index) and cognitive function (assessed by trained staff using a 
computerized cognitive test battery [CogState Ltd, Melbourne, Australia] to 
measure psychomotor function, attention, working memory and learning).  
 
Statistical methodology 
The planned sample size is described in Appendix A. Efficacy analyses were 
performed on the full analysis set (FAS; patients who received ≥1 dose of 
solifenacin and provided valid baseline and ≥1 post-baseline values for the 
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primary efficacy endpoint). Safety analyses were performed on the safety 
analysis set (SAF; patients who received ≥1 solifenacin dose). All statistical 
analyses used SAS® version 9.1.3 or higher. Demographics and baseline 
characteristics and efficacy and safety data were summarized by descriptive 
statistics. Unless mentioned otherwise, changes from baseline to week 24 in 
primary and secondary efficacy endpoints were analyzed using a paired two-
sided t-test at α = 0.05 significance level. The Wilcoxon signed-rank test was 
used to analyze the statistical significance of change from baseline to week 24 
in bladder volume and in exploratory analyses where MCC was expressed as a 
percentage of EBC or MCV. Missing data were not imputed. 
 
Results 
Patient demographics and dosing 
A total of 23 patients aged 6 months–<5 years and 76 patients aged 5–<18 
years were enrolled (Appendix Fig. A); all were included in the SAF. Of these, 
21 and 55 patients aged 6 months–<5 years and 5–<18 years, respectively, had 
valid baseline and post-baseline measurements for MCC and were included in 
the FAS (exclusions listed in Appendix Table B). Mean age was 35.3 months (6 
months–<5 years age group), and 10.8 years (5–<18 years age group; Table 1). 
More than half of the patients were female (60.9% aged 6 months–<5 years; 
51.3% aged 5–<18 years). 
Overall, 14 (66.7%) and 41 (70.7%) patients aged 6 months–<5 years and 5–
<18 years, respectively, were receiving a PED10 dose of solifenacin by week 
52. 
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Efficacy assessments 
After 24 weeks’ solifenacin treatment, there was a statistically significant 
increase in MCC versus baseline in patients aged 6 months–<5 years and 5–
<18 years (mean [standard deviation (SD)]: 37.0 [35.9] ml and 57.2 [107.7 ml, 
respectively; P < 0.001; Fig. 2). Improvement in MCC was also observed after 
52 weeks’ treatment in patients aged 6 months–<5 years and 5–<18 years 
(mean [SD]: 58.6 [34.1] ml and 51.0 [102.9] ml, respectively). 
Compared with baseline, at 24 weeks, solifenacin treatment significantly 
improved bladder compliance in patients aged 6 months–<5 years and 5–<18 
years (mean [SD]: 5.1 [6.8] ml/cmH2O, P = 0.003 and 9.1 [28.6] ml/cmH2O, P = 
0.029, respectively), increased bladder volume until first detrusor contraction 
(>15 cmH2O) expressed as a percentage of EBC (P = 0.001, P < 0.001, 
respectively) and decreased the number of overactive detrusor contractions 
(mean [SD]: −7.0 [8.6], P = 0.001 and −2.3 [5.1], P = 0.003, respectively; 
Appendix Fig. B). Compared with baseline, at 24 weeks there was a decrease 
in the number of patients reaching a detrusor pressure threshold of 30 cmH2O 
in both age groups (from seven to three of 21 children aged 6 months–<5 years 
and from 25 of 55 to 22 of 49 patients aged 5–<18 years). For those reaching 
30 cmH2O at both baseline and week 24 there was an increase in bladder 
volume (mean [SD] change: 67.5 [118] mL, P = 0.567 [6 months–<5 years]; 
61.8 [80.6] mL; P = 0.006 [5–<18 years]). 
There were significant improvements in diary endpoints at week 24 versus 
baseline: MCV/24 h increased (mean [SD]: 40.6 [51.5] ml, P = 0.004 and 67.5 
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[88.1] ml, P < 0.001, respectively) and number of incontinence episodes/24 h 
decreased (mean [SD]: −1.3 [1.4], P = 0.001 and −1.6 [2.0], P < 0.001, 
respectively). Improvements were sustained up to 52 weeks. 
In both age groups, solifenacin treatment significantly increased MCC 
expressed as a percentage of EBC or MCV from baseline to week 24 (mean 
[SD]: EBC, 35.1 [35.7], P < 0.001 and 16.3 [31.0], P < 0.001, respectively; MCV, 
62.4 [92.7] ml, P = 0.002 and 37.5 [62.1] ml, P < 0.001, respectively; Appendix 
Fig. C). 
 
Safety assessments 
The incidences of drug-related TEAEs were 21.7% and 19.7% in patients aged 
6 months–<5 years and 5–<18 years, respectively (Table 2). In both age 
groups, the most common drug-related TEAE was constipation. All drug-related 
TEAEs were considered mild-to-moderate in intensity. Serious AEs were 
reported in three patients aged 6 months–<5 years and seven patients aged 5–
<18 years, respectively (Appendix Table C); none were considered to be 
solifenacin related. 
There were no clinically relevant changes in blood pressure, heart rate, body 
temperature, or laboratory parameters. Compared with baseline, all changes in 
vital signs were consistent with normal age-adjusted ranges at week 52 
(Appendix Table D). Moreover, according to the investigator, there were no 
clinically relevant changes in ultrasound assessments of the upper urinary tract. 
Height and weight increases were consistent with standard norms. 
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Most 12-lead ECGs were considered to be normal, and no abnormality was 
assessed as clinically significant. Mean changes from baseline to week 52 for 
all ECG measurements were negligible in patients from both age groups 
(Appendix Table E). Four patients aged 5–<18 years were discontinued from 
treatment (Appendix Table F) as a result of an observed increase in QT interval 
corrected for heart rate by Bazett’s formula (QTcB) above the pre-specified 
discontinuation threshold of 30 ms relative to mean baseline value. In repeat 
ECG measures, this threshold was within normal intra-patient variation. At week 
52, all patients, except one aged 5–<18 years, had a categorized absolute 
QTcB value <450 ms (Appendix Table G). 
In patients aged 5–<18 years, age-related improvements were observed in 
ocular accommodation (mean [SD] accommodative error index: baseline 1.88 
[2.44] diopters; week 52 1.24 [0.52] diopters) and cognitive function (Appendix 
Table H). 
 
Discussion 
The studies reported herein are the first long-term multicenter investigations to 
demonstrate efficacy and safety of solifenacin in pediatric patients with NDO. 
There was a significant increase in the primary endpoint of MCC at week 24 
and improvements were noted in secondary urodynamic and diary endpoints 
over 52 weeks’ treatment. Our results support those from a study in pediatric 
patients with NDO who were refractory to oxybutynin or tolterodine [17]. 
MCC was selected as the primary efficacy endpoint as it is the most 
reproducible urodynamic parameter and to allow comparison with previous 
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oxybutynin studies [22,23]. The observed increases in both our studies are 
considered to be clinically relevant and demonstrate that a larger volume of fluid 
can be accommodated in the bladder prior to reaching intravesical pressures 
associated with leakage or discomfort. Increases in MCC are accepted as 
indicating a lower risk of high intravesical pressure and the associated potential 
for renal damage [24]. While the magnitude of the increase in MCC at week 24 
was smaller in patients aged 6 months–<5 years versus 5–<18 years, this is 
considered to be a reflection of the smaller bladder size in the younger group 
[25]. The mean increases in MCC expressed as a percentage of EBC, or 
relative to individual bladder capacity estimated from the MCV, were greater in 
patients aged 6 months–<5 years versus older patients, although significant 
improvements from baseline were observed for all patients. These analyses 
suggest that solifenacin is at least equally effective across the younger and 
older age groups and demonstrate the benefit of early treatment initiation with 
an optimal dose. Similar trends in MCC improvement were observed in 
oxybutynin-treated pediatric patients with NDO [22,26]. 
Bladder compliance is a calculated parameter that reflects the relationship 
between bladder volume and pressure [1]. Solifenacin treatment increased 
bladder compliance in both populations, and thereby, the ability of the bladder 
to accommodate larger volumes before a deleterious increase in bladder 
pressure develops. Bladder compliance increases with age: 10 ml/cm H2O is 
considered normal for infants [27], >10 ml/cm H2O for children [28], and >25 
ml/cm H2O for adolescents and adults [29], which explains the lower baseline 
compliance in our younger patients. 
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The decrease in the number of overactive detrusor contractions alongside an 
increase in median bladder volume until first detrusor contraction expressed as 
a percentage of EBC suggests that solifenacin is effective in preventing 
involuntary detrusor contractions in pediatric patients with NDO. This is a key 
treatment goal as a later onset of overactive contractions can lead to reductions 
in incontinence and reductions in the number of overactive contractions of the 
bladder wall, thereby indirectly decreasing the likelihood of upper urinary tract 
infection and subsequent renal injury. 
Solifenacin treatment improved MCV, which is indicative of maximum bladder 
capacity under normal physiological conditions. In both age groups, the 
magnitude of the increase from baseline to week 24 in MCV was similar to the 
magnitude of change in MCC, demonstrating ‘real-world’ relevance of the 
urodynamic findings. Moreover, solifenacin reduced incontinence, an important 
secondary NDO treatment goal, which is consistent with the decrease in 
incidence of involuntary contractions and increase in MCC. 
The observed findings in pediatric patients are consistent with those in adults 
with NDO. In the prospective, placebo-controlled SOlifenacin in NeurogenIC 
detrusor overactivity (SONIC) study, solifenacin treatment improved the mean 
changes from baseline in MCC and bladder volume at first contraction and at 
first leak, in patients aged 18–65 years with NDO due to multiple sclerosis or 
spinal cord injury [14]. Additionally, in a retrospective analysis of case histories 
and urodynamic data from 35 patients with spinal cord injury, solifenacin 
treatment significantly improved bladder capacity, detrusor compliance, and 
reflex volume [30]. 
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All doses of solifenacin were well tolerated, and the safety profiles in both age 
groups were comparable. The overall incidences of drug-related TEAEs were 
low, including those of the typical antimuscarinic side effects of constipation and 
dry mouth, and CNS-related side effects. These observations are in accordance 
with other studies in which solifenacin has demonstrated the potential for 
improved tolerability versus oxybutynin, especially for dry mouth [14] and 
cognition [31] in adults and for facial flushing, dry mouth and cognition in 
children [8]; these adverse effects of oxybutynin, particularly those on cognition, 
may require close patient monitoring [8]. The potential for cognitive adverse 
effects are highlighted by the results of an in vivo study which indicated that 
oxybutynin displays higher muscarinic receptor occupancy in the brain and 
greater blood-brain barrier penetration than solifenacin [32]. 
Importantly, we observed no clinically relevant changes in blood pressure, heart 
rate, or ECG parameters. Treatment discontinuation by four patients who 
exceeded the pre-specified QTcB criteria was considered to be a consequence 
of random variation in repeat ECG measures and unlikely to be due to 
solifenacin treatment. There were no clinically relevant changes in laboratory 
parameters including markers of renal function, demonstrating that kidney 
function was protected during 52 weeks of solifenacin treatment. 
In the present study, age-related improvements were observed in both ocular 
accommodation and cognitive function. The improvements in ocular 
accommodation were an unexpected finding given that anticholinergic drugs 
inhibit iris sphincter and ciliary muscle stimulation, which can lead to mydriasis 
and cycloplegia. The improvements in cognitive function were anticipated owing 
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to the rapid cognitive maturation that occurs during late childhood and 
adolescence. 
A limitation of our studies is the open-label design, which may introduce bias 
through unblinding. Use of placebo was not feasible because it is considered 
unethical to withhold treatment from patients with NDO for more than a few 
weeks. The studies were designed to limit the number of pediatric patients 
exposed to treatment while being adequately powered to demonstrate a 
clinically meaningful change in the primary efficacy endpoint. 
 
Conclusions 
Solifenacin is effective and well tolerated in pediatric patients with NDO, aged 6 
months–<18 years. With the advantage of a flexible dosing formulation and no 
adverse ophthalmologic or cognitive effects, these first, long-term studies of 
solifenacin for NDO in a pediatric population demonstrate that the therapeutic is 
a potential alternative to oxybutynin, the current standard of care, especially in 
children aged <5 years, where there were previously no other NDO 
pharmacotherapies. Indeed, in Europe, the data from the studies presented 
herein contributed towards the approval of solifenacin for NDO in patients aged 
2–18 years. 
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Table 1 Baseline demographics (SAF). 
Category 6 months–<5 years 
(n = 23) 
5–<18 years 
(n = 76) 
Sex, n (%)   
 Male 9 (39.1) 37 (48.7) 
 Female 14 (60.9) 39 (51.3) 
Ethnicity, n (%)   
 Hispanic or Latino 2 (8.7) 11 (14.5) 
 Not Hispanic or Latino 21 (91.3) 65 (85.5) 
Race, n (%)   
 White 12 (52.2) 45 (59.2) 
 Black/African American 0 2 (2.6) 
 Asian 11 (47.8) 23 (30.3) 
 American Indian/Alaskan 
Native 
0 1 (1.3) 
 Others 0 5 (6.6) 
Mean agea, months/years (SD) 35.3 months (12.7) 10.8 years (3.3) 
Weighta (kg) 13.2 (2.9) 38.1 (15.5) 
Heighta (cm) 89.3 (9.2) 138 (16.3) 
Mean BMI, kg/m2 16.5 (2.2) 19.2 (4.7) 
Medical condition, n (%)b   
Lipomeningocele NR 7 (9.2) 
Meningomyelocele NR 26 (34.2) 
Spina bifida 23 (100)b 9 (11.8) 
Spinal deformity NR 24 (31.6) 
Other NR 10 (13.2) 
Wheelchair bound, n (%) NR 33 (43.4) 
Spina bifida closure surgery, n 
(%) 
23 (100) 64 (84.2) 
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Previous antimuscarinic 
medication, n (%) 
14 (60.9)a,c 73 (96.1)a,d 
Oxybutynin 5 (21.7) 29 (38.2) 
Propiverine 2 (8.7) 19 (25.0) 
Solifenacin 7 (30.4) 24 (31.6) 
Tolterodine – 6 (7.9) 
Reason for discontinuing 
previous antimuscarinic 
medication, n (%) 
14 (60.9)a 73 (96.1)a 
Washout for current study 13 (56.5) 11 (14.5) 
Lack of efficacy – 1 (1.3) 
Unknown 1 (4.3) 61 (80.3) 
a Measured at screening. 
b Spina bifida diagnosis was not differentiated. 
c Two further patients received antimuscarinic medication prior to screening. 
d All patients included in the SAF had taken previous antimuscarinic medication. 
Three further patients received medication prior to screening. 
BMI, body mass index; NR, not recorded; SAF, safety analysis set; SD, 
standard deviation. 
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Table 2 Incidence of drug-related TEAEs (SAF). 
 Patients, n (%) 
 6 months–<5 years 
(n = 23) 
5–<18 years 
(n = 76) 
Overall 5 (21.7) 15 (19.7) 
Constipation 3 (13.0) 6 (7.9) 
Dry mouth 2 (8.7) 2 (2.6) 
ECG QT prolonged 0 3 (3.9) 
UTI 1 (4.3)a 1 (1.3) 
Abdominal pain 0 1 (1.3) 
Bacterial test positive 1 (4.3)b 0 
Pharyngotonsillitis 0 1 (1.3) 
Somnolence 0 1 (1.3) 
Viral rash 0 1 (1.3) 
a One patient experienced three TEAEs of Escherichia UTI, UTI bacterial, and 
UTI enterococcal. 
b Reported as bacteria in urine. Positive bacterial test was considered by the 
investigator to be related to solifenacin. 
ECG, electrocardiogram; SAF, safety analysis set; TEAE, treatment-emergent 
adverse event; UTI, urinary tract infection. 
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Figure legends 
Fig. 1 Study design. 
a Included washout (five half-lives) and diary completion for the 3 days before 
visit 2 and all subsequent visits. 
b Washout was for 14 days and diary completion occurred for the 7 days before 
visit 2 and all subsequent visits. 
c For patients aged 6 months–<2 years, treatment began on the day of the 
baseline visit; for patients aged ≥2–<5 years and 5–<18 years, treatment began 
on the day after the baseline visit.  
d If the optimal dose was determined in <12 weeks, the fixed-dose assessment 
period was extended to keep the entire treatment period at 52 weeks. 
Fig. 2 MCC of patients aged 6 months–<5 years and 5–<18 years at baseline 
and week 24 (primary endpoint) and week 52 (secondary endpoint; FAS). 
Data were analyzed using a paired two-sided t-test at α = 0.05 significance 
level. 
CI, confidence interval; FAS, full analysis set; MCC, maximum cystometric 
capacity; SD, standard deviation. 
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Fig. 1 Study design.
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Fig. 2 MCC of patients aged 6 months–<5 years and 5–<18 years at baseline 
and week 24 (primary endpoint) and week 52 (secondary endpoint; FAS). 
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Appendix A Planned sample size. 
The planned sample size was approximately 24 patients aged 6 months–<5 
years; ≥20 patients provided 59–84% power to detect a statistically 
significant difference from baseline to week 24 of between 52 ml and 70 
ml in maximum cystometric capacity (MCC), with a standard deviation 
(SD) of 100 ml. Similarly, 50 patients aged 5–<18 years were planned to 
be enrolled. A total of 44 patients provided 90% power to detect a 
statistical significant difference from baseline to week 24 of ≥52 ml, with 
a SD not >103 ml [1,2]. 
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Appendix Table A Inclusion and exclusion criteria. 
Inclusion criteria in patients aged 6 months–<5 years Exclusion criteria in patients aged 6 months–<5 years 
At screening 
 Male or female aged 6 months–<5 years 
 Minimum weight: 6 kg 
 Previous myelomeningocele 
 Documented diagnosis of NDO confirmed by 
urodynamic assessments at baseline 
 Previous history of DSD 
 Practicing CIC 
 Adjudged suitable for a regimen of four to six CICs per 
day fixed for the duration of the study 
 Able to swallow the study drug 
 
 36 
 
 Patient’s parent(s)/legal representative(s) were able to 
comply with the study requirements and the concomitant 
medication restrictions 
 Written informed consent had to be obtained from the 
patient’s parent(s)/legal guardian(s) prior to any study-
related procedures 
 Patient’s parent(s)/legal representative(s) agreed not to 
allow patient to participate in another interventional 
study while on treatment and throughout the pre-
treatment period 
At screening or baseline 
 
 Bladder capacity <25% of expected age-related capacity 
 Vesicoureteral reflux Grade 3 to 5a 
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 Known genitourinary condition (other than NDO) that might 
have caused incontinence 
 Indwelling urinary catheter within 4 weeks prior to study 
visit 
 Undergone bladder augmentation surgery 
 Surgically-corrected underactive sphincter 
 Electrostimulation within 2 weeks prior to the visit 
 Received intravesical botulinum toxin within 9 months prior 
to screening 
 UTI confirmed by urinalysis (urine culture containing 
>100 000 cfu/ml) at baseline 
 Used prohibited medications 
 Kidney/bladder stones or other pathology causing urinary 
symptoms 
 Central or congenital nephrogenic diabetes insipidus 
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 Bowel dysfunction, unless the condition was being actively 
managed 
 Fecal impaction 
 Severe gastrointestinal condition, partial/complete bowel 
obstruction, decreased motility, or at risk for gastric 
retention 
 History of glaucoma 
 Known or suspected hypersensitivity to solifenacin, any of 
the excipients used, or previous severe hypersensitivity to 
any drug 
 Malnutrition or severely overweight 
 QTcB >440 ms, a history of QTc prolongation, or at risk of 
QT prolongation 
 Severe renal impairment (GFR <30 ml/min) 
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 AST or ALT ≥2 times the ULN, or total bilirubin ≥1.5 times 
the ULN 
 Any other clinically significant out-of-range urinalysis, 
biochemistry, or hematology results 
 Current or previous history of epilepsy 
 History or presence of any malignancy 
 Clinically significant or unstable medical condition, which 
precluded the patient’s participation 
 Participated in another clinical trial and/or had taken an 
investigational drug within 30 days (or five half-lives of the 
drug, or the limit set by national law, whichever was longer) 
prior to the visit 
 Parent(s)/legal representative(s) of the patient was an 
employee of the Astellas Group, the CRO involved, or the 
investigator site that executed the study 
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 Breast-fed by a woman taking any prohibited 
medication/fed with a milk product in which the presence of 
prohibited medication ingredients could not be excluded 
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Inclusion criteria in patients aged 5–<18 years Exclusion criteria in patients aged 5–<18 years 
At screening 
 Male or female aged 5–<18 years 
 Documented diagnosis of NDO 
 Patient and patient’s parent(s)/legal guardian(s) were able 
to comply with the study requirements and the concomitant 
medication restrictions 
 Practicing CIC 
 Adjudged suitable for a regimen of four to six CICs per day 
fixed for the duration of the study 
 Treated with an antimuscarinic drug for ≥6 months 
 Weight was within normal percentiles for their age 
 Bowel dysfunction had to be actively managed in afflicted 
individuals 
 Breastfeeding, pregnant, or intended to become pregnant 
 Known genitourinary condition (other than NDO) that might 
have caused incontinence 
 Undergone bladder augmentation surgery 
 Bladder capacity <25% of expected age-related capacity 
 Electrostimulation within 2 weeks prior to screening and at 
any time during the study 
 Vesicoureteral reflux Grade 3 to 5a 
 Kidney/bladder stones or other pathology causing urinary 
symptoms 
 Indwelling urinary catheter within 4 weeks prior to screening 
 42 
 
 Able to swallow the study medication 
 Sexually active female patients of childbearing potential 
agreed to use a reliable form of birth control for the 
duration of the study and for ≥1 month afterwards. Sexually 
active male patients agreed to use a condom for the 
duration of the study and for ≥1 month afterwards 
 Written informed consent had to be obtained from the 
patient’s parent(s)/legal representative(s) prior to any 
study-related procedures; assent (patient) where 
appropriate was given 
 Agreed not to participate in another interventional study 
while on treatment 
 
 One of the following gastrointestinal problems: partial or 
complete bowel obstruction, decreased motility, or at risk of 
gastric retention 
 Existing fecal impaction 
 QTcB >440 ms, a history of QTc prolongation, or at risk of QT 
prolongation 
 History or presence of any malignancy within 5 years prior to 
screening; any relevant history or presence of malignancy 
related to urogenital tract 
 Clinically significant or unstable medical condition or disorder, 
which, in the opinion of the investigator, precluded the 
patient’s participation 
 Central or congenital nephrogenic diabetes insipidus 
 Severe renal impairment (GFR <30 ml/min) 
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 AST or ALT ≥2 times the ULN, or total bilirubin ≥1.5 times the 
ULN 
 Any other clinically significant out-of-range urinalysis, 
biochemistry, or hematology results 
 Known or suspected hypersensitivity to solifenacin (or other 
antimuscarinics), any of the excipients used, or previous 
severe hypersensitivity to any drug 
 Participated in another clinical trial and/or had taken an 
investigational product within 30 days (or five half-lives of the 
drug, or the limit set by national law, whichever was longer) 
prior to screening 
 Used prohibited medications and restricted medications, 
when the conditions for restricted medications were not met 
 Received intravesical botulinum toxin within 9 months prior to 
screening 
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 Parent(s)/legal representative(s) of the patient was an 
employee of the Astellas Group, the CRO involved, or the 
investigator site that executed the study 
 History of glaucoma 
At baseline 
 Diagnosis of NDO had to be confirmed by urodynamics 
demonstrating the presence of involuntary detrusor 
contractions involving a detrusor pressure increase 
>15 cmH2O above baseline 
 UTI confirmed by urinalysis (urine culture containing 
>100 000 cfu/ml) 
 Recurrent UTI between screening and baseline 
 DSD or surgically corrected underactive urethral sphincter 
and did not meet the urodynamic inclusion criteria for NDO 
a Vesicoureteral reflux Grade 1 and 2 was not included in the exclusion criteria due to urodynamic filling. Ureters are low-
resistance vessels and in patients with substantial ureteral reflux, not only the bladder but also the ureters are filled at 
cystometry. This results in a maximum infusion volume not representing maximum cystometric capacity. 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CIC, clean intermittent catheterization; CRO, contract 
research organization; DSD, detrusor sphincter dyssynergia; GFR, glomerular filtration rate; NDO, neurogenic detrusor 
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overactivity; QTc, QT interval corrected for heart rate; QTcB, QT interval corrected for heart rate by Bazett’s formula; ULN, 
upper limit of normal; UTI, urinary tract infection. 
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Appendix Table B Reasons for exclusion from FAS. 
Reasons for exclusion Patients, n  
6 months–<5 years 
(n = 23) 
5–<18 years 
(n = 76) 
Overall 2a 21 
Early withdrawal at baseline   
 UTI 0 6 
 QTcB prolongation 1 7 
 Withdrawal by patient 0 1 
First urodynamic assessment after solifenacin intake 0 3 
Non-eligibility for urodynamic assessment   
 No baseline urodynamic assessment 0 1 
 UTI during post-baseline assessment 0 1 
 Inconsistent filling rates between baseline and post-baseline urodynamic 
assessment 
0 1 
 Unreliable baseline urodynamic trace because of abdominal pressure changes 0 1 
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a The reason for exclusion was unknown for one patient. 
FAS, full analysis set; QTcB, QT interval corrected for heart rate by Bazett’s formula; UTI, urinary tract infection. 
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Appendix Table C Incidence of SAEs (SAF). 
 Patients, n 
 6 months–<5 years 
(n = 23) 
5–<18 years 
(n = 76) 
Overall 3 7 
 Dengue fever 0 1 
 Hypertension 0 1 
 Megacolon 0 1 
 Orchitis 0 1 
 Pharyngitis 1 0 
 Spinal cord operation 0 1 
 Tachycardia 0 1 
 Teratoma 1 0 
 Tethered cord syndrome 0 1 
 UTI bacterial 0 1 
 UTI NOS 1 0 
 Vomiting 1 0 
Patients may have experienced >1 SAE. 
NOS, not otherwise specified; SAE, serious adverse event; SAF, safety analysis 
set; UTI, urinary tract infection. 
  
 49 
 
Appendix Table D Vital signs (SAF). 
 6 months–<5 years 
(n = 23) 
5–<18 years 
(n = 76) 
Mean systolic blood pressure, mmHg 
 Baseline (SD) 97.1 (10.4) 108 (12.3) 
 Week 52 (SD) 102 (11.4) 108 (11.9) 
 Change from baseline (SD) 4.7 (10.2) −0.0 (11.1) 
Mean diastolic blood pressure, mmHg 
 Baseline (SD) 63.1 (6.4) 69.1 (11.1) 
 Week 52 (SD) 64.9 (10.0) 67.1 (10.3) 
 Change from baseline (SD) 1.6 (8.2) −1.7 (9.9) 
Mean pulse rate, bpm   
 Baseline (SD) 113 (17.4) 89.3 (18.0) 
 Week 52 (SD) 109 (14.0) 87.9 (14.3) 
 Change from baseline (SD) −3.2 (11.6) −2.2 (12.3) 
Mean body temperature, oC   
 Baseline (SD) 36.5 (0.3) 36.4 (0.4) 
 Week 52 (SD) 36.6 (0.3) 36.4 (0.4) 
 Change from baseline (SD) 0.1 (0.3) 0.0 (0.4) 
SAF, safety analysis set; SD, standard deviation. 
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Appendix Table E 12-lead ECGs (SAF). 
Criteria 6 months–<5 years 
(n = 23) 
5–<18 years 
(n = 76) 
PR duration (ms) 
 Baseline, mean (SD) 125 (12.6) 135 (14.4) 
 Week 52, mean (SD) 126 (13.4) 140 (15.0) 
 Change from baseline, mean (SD) 0.7 (6.6) 3.5 (7.3) 
RR duration (ms) 
 Baseline, mean (SD) 560 (57.5) 711 (147) 
 Week 52, mean (SD) 561 (73.6) 735 (130) 
 Change from baseline, mean (SD) −0.7 (61.4) 30.4 (106) 
QRS duration (ms) 
 Baseline, mean (SD) 76.8 (4.2) 84.1 (5.3) 
 Week 52, mean (SD) 76.5 (5.3) 84.9 (4.2) 
 Change from baseline, mean (SD) 0.0 (3.7) 0.8 (3.7) 
QT duration 
 Baseline, mean (SD) 312 (14.5) 350 (31.1) 
 Week 52, mean (SD) 315 (15.0) 356 (30.0) 
 Change from baseline, mean (SD) 3.3 (14.6) 7.9 (23.8) 
QTcB (ms) 
 Baseline, mean (SD) 419 (13.3) 419 (16.7) 
 Week 52, mean (SD) 422 (13.0) 418 (18.9) 
 Change from baseline, mean (SD) 4.7 (13.0) 0.3 (12.5) 
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QTcF (ms) 
 Baseline, mean (SD) 380 (10.9) 394 (15.1) 
 Week 52, mean (SD) 383 (8.0) 395 (17.4) 
 Change from baseline, mean (SD) 4.2 (10.0) 3.2 (11.8) 
Heart rate (beats/min) 
 Baseline, mean (SD) 109 (10.9) 88.2 (17.4) 
 Week 52, mean (SD) 109 (13.4) 84.6 (16.2) 
 Change from baseline, mean (SD) 0.3 (11.9) −3.94 (12.7) 
The baseline value is the mean of the triplicate ECG measurements at visit 1 
and visit 2 for patients aged 6 months–<5 years and visit 2 and visit 3 for 
patients aged 5–<18 years. 
ECG, electrocardiogram; QTcB, QT interval corrected for heart rate by Bazett’s 
formula; QTcF, QT interval corrected for heart rate by Fridericia’s formula; SAF, 
safety analysis set; SD, standard deviation. 
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Appendix Table F Treatment discontinuation (SAF). 
Parameter Category Patients, n (%) 
6 months–<5 years 
(n = 23) 
5–<18 years 
(n = 76) 
Treatment discontinuation Yes 2 (8.7) 18 (23.7) 
 No 21 (91.3) 58 (76.3) 
Primary reason for discontinuation Registered but never 
received/dispensed study drug 
0 0 
 AE 0 4 (5.3) 
 Lack of efficacy 1 (4.3) 0 
 Protocol violationa 1 (4.3) 10 (13.2) 
 Withdrawal by patient 0 4 (5.3) 
a The baseline test results were only available a few days after baseline. These patients should not have started the study due 
to exclusion criteria violations (6 months–<5 years: one patient had an average QTcB >440 ms, a history of QTc prolongation, 
or was at risk of QT prolongation; 5–<18 years: six patients had UTIs at baseline and four patients had an average QTcB >440 
ms, a history of QTc prolongation, or were at risk of QT prolongation). 
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AE, adverse event; QTc, QT interval corrected for heart rate; QTcB, QT interval corrected for heart rate by Bazett’s formula; 
SAF, safety analysis set; UTI, urinary tract infection. 
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Appendix Table G Change from baseline in QTcB (SAF). 
 
Criteria 
6 months–<5 years 
(n = 23) 
5–<18 years 
(n = 76) 
Value at baseline, n (%)   
 N 23 76 
 <450 ms 22 (95.7) 76 (100) 
 450–<480 ms 1 (4.3) 0 
Value at week 52, n (%)   
 N 20 57 
 <450 ms 20 (100.0) 56 (98.2) 
 450–<480 ms 0 1 (1.8) 
Change from baseline to week 52, n (%)   
 N 20 57 
 <0 9 (45.0) 29 (50.9) 
 0–<30 ms 9 (45.0) 27 (47.4) 
 30–<60 ms 2 (10.0) 1 (1.8) 
QTcB, QT interval corrected for heart rate by Bazett’s formula; SAF, safety 
analysis set. 
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Appendix Table H Change from baseline in cognitive function (SAF). 
Testa  Change from baseline in score 
24 weeks 52 weeks 
Score P Score P 
Detection test −0.04 < 0.001 −0.05 < 0.001 
Identification test −0.03 0.012 −0.05 < 0.001 
One card learning test 0.02 0.268 0.05 0.007 
One back test −0.03 0.005 −0.04 < 0.001 
a Decrease from baseline indicates an improvement except for the one card 
learning test where an increase in score is indicative of improvement. 
SAF, safety analysis set. 
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Appendix Fig. A Patient disposition. 
a Any enrolled patient who discontinued the study at/prior to visit 2, or who 
entered the washout period, but subsequent results from visit 2 indicated that 
the patient was not eligible to enter the washout period and thereby 
discontinued the study.  
b Any patient who was not a screening failure and who discontinued the study 
at/prior to visit 3, or who entered the treatment period but did not take any dose 
of solifenacin and discontinued the study because subsequent results from visit 
3 indicated that the patient was not eligible to enter the treatment period. 
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Appendix Fig. B Secondary efficacy variables in patients aged 6 months–<5 
years and 5–<18 years: (A) bladder compliance, (B) bladder volume until first 
detrusor contraction (>15 cmH2O) as a percentage of EBC, (C) number of 
overactive detrusor contractions (>15 cmH2O) until leakage or end of bladder 
filling, (D) MCV/24 h and (E) incontinence episodes/24 h (FAS). 
Bladder compliance was calculated by dividing volume change by change in 
detrusor pressure [1]. If an overactive contraction was noted, the underlying 
basal detrusor pressure was used. Filling rates were defined as 5% of the 
patient’s MCV (6 months–<2 years), 5% of the EBC (2–<5 years), or 30 ml/min 
(5–<18 years) except for patients with capacities of approximately 150 ml (15 
ml/min). EBC was calculated using Hjälmås formula [2] (30 + [age in years x 30] 
[maximum 390 ml]). 
Data were analyzed using a paired two-sided t-test at α = 0.05 significance 
level. 
a Post hoc analysis was performed to include patients who did not have 
detrusor contraction.  
b Wilcoxon signed-rank test was used to analyze the statistical significance of 
the median change from baseline in bladder volume.  
c Change in MCV from baseline to week 24 and week 52 was evaluated in 18 
and 16 patients aged 6 months–<5 years, respectively; and 51 and 49 patients 
aged 5–<18 years, respectively.  
d Change in incontinence episodes/24 h from baseline to week 24 and week 52 
was evaluated in 17 and 14 patients aged 6 months–<5 years, respectively; and 
51 and 49 patients aged 5–<18 years, respectively. 
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CI, confidence interval; EBC, expected bladder capacity; FAS, full analysis set; 
MCV, maximum catheterized volume; SD, standard deviation. 
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Appendix Fig. C MCC expressed as a percentage of (A) EBC and (B) MCV. 
 
EBC, expected bladder capacity; MCC, maximum cystometric capacity; MCV, 
maximum catheterized volume; SD, standard deviation. 
 
 
